In last trading session, Dare Bioscience, Inc. (NASDAQ:DARE) saw 2,328,106 shares changing hands with its beta currently measuring 1.95. Company’s recent per share price level of $1.32 trading at $0.09 or 7.32% at ring of the bell on the day assigns it a market valuation of $50.15 Million. That closing price of DARE’s stock is at a discount of -68.18% from its 52-week high price of $2.22 and is indicating a premium of 43.18% from its 52-week low price of $0.75. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 572.76 Million shares which gives us an average trading volume of 532.04 Million if we extend that period to 3-months.
For Dare Bioscience, Inc. (DARE), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2. Splitting up the data highlights that, out of 4 analysts covering the stock, none rated the stock as a Sell while none recommended an Overweight rating for the stock. None suggested the stock as a Hold whereas 4 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.14 in the current quarter.
Dare Bioscience, Inc. (NASDAQ:DARE) trade information
Upright in the green today for gaining 7.32%, in the last five days DARE remained trading in the green while hitting it’s week-highest on Thursday, Nov 19 when the stock touched $1.39 price level, adding 5.04% to its value on the day. Dare Bioscience, Inc.’s shares saw a change of 60.98% in year-to-date performance and have moved 23.36% in past 5-day. Dare Bioscience, Inc. (NASDAQ:DARE) showed a performance of 26.92% in past 30-days. Number of shares sold short was 250.36 Million shares which calculate 0.47 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $5.13 to the stock, which implies a rise of 288.64% to its current value. Analysts have been projecting $3 as a low price target for the stock while placing it at a high target of $7.5. It follows that stock’s current price would jump +468.18% in reaching the projected high whereas dropping to the targeted low would mean a loss of 127.27% for stock’s current value.
Dare Bioscience, Inc. (DARE) estimates and forecasts
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 43% during past 5 years. In 2020, company’s earnings growth rate is likely to be around 38% while estimates for its earnings growth in next 5 years are of 0%
Dare Bioscience, Inc. (NASDAQ:DARE)’s Major holders
Insiders are in possession of 8.3% of company’s total shares while institution are holding 5.95% percent of that, with stock having share float percentage of 6.49%. Investors also watch the number of corporate investors in a company very closely, which is 22 institutions for Dare Bioscience, Inc. that are currently holding shares of the company. Vanguard Group, Inc. (The) is the top institutional holder at DARE for having 836.88 Thousand shares of worth $835.8 Thousand. And as of September 29, 2020, it was holding 2.2% of the company’s outstanding shares.
The second largest institutional holder is Renaissance Technologies, LLC, which was holding about 703.6 Thousand shares on September 29, 2020. The number of shares represents firm’s hold over 1.85% of outstanding shares, having a total worth of $702.69 Thousand.
On the other hand, Vanguard Balanced Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of June 29, 2020, the former fund manager was holding 132692 shares of worth $131.18 Thousand or 0.35% of the total outstanding shares. The later fund manager was in possession of 109.63 Thousand shares on June 29, 2020, making its stake of worth around $108.38 Thousand in the company or a holder of 0.29% of company’s stock.